Cowen & Co. Thinks Pieris Pharmaceuticals’ Stock is Going to Recover


Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Pieris Pharmaceuticals (PIRS) today. The company’s shares opened today at $3.21, close to its 52-week low of $2.39.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.1% and a 46.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Nektar Therapeutics.

Pieris Pharmaceuticals has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

Based on Pieris Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.15 million. In comparison, last year the company had a net profit of $7.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pieris Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with an unmet medical need.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts